BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

772 related articles for article (PubMed ID: 11987030)

  • 1. Molecular and biochemical screening for the diagnosis and management of medullary thyroid carcinoma in multiple endocrine neoplasia type 2A.
    Vieira AE; Mello MP; Elias LL; Lau IF; Maciel LM; Moreira AC; Castro M
    Horm Metab Res; 2002 Apr; 34(4):202-6. PubMed ID: 11987030
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Very early detection of RET proto-oncogene mutation is crucial for preventive thyroidectomy in multiple endocrine neoplasia type 2 children: presence of C-cell malignant disease in asymptomatic carriers.
    Sanso GE; Domene HM; Garcia R; Pusiol E; de M; Roque M; Ring A; Perinetti H; Elsner B; Iorcansky S; Barontini M
    Cancer; 2002 Jan; 94(2):323-30. PubMed ID: 11900218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Early diagnosis of multiple endocrine neoplasia type 2 (MEN 2) by detection of mutated RET proto-oncogene carriers].
    Sansó G; Domené HM; Iorcansky S; Barontini M
    Medicina (B Aires); 1998; 58(2):179-84. PubMed ID: 9706252
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Familial medullary thyroid carcinoma: not a distinct entity? Genotype-phenotype correlation in a large family.
    Moers AM; Landsvater RM; Schaap C; Jansen-Schillhorn van Veen JM; de Valk IA; Blijham GH; Höppener JW; Vroom TM; van Amstel HK; Lips CJ
    Am J Med; 1996 Dec; 101(6):635-41. PubMed ID: 9003111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome).
    Oishi S; Sato T; Takiguchi-Shirahama S; Nakamura Y
    Endocr J; 1995 Aug; 42(4):527-36. PubMed ID: 8556060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rudolf-Virchow-Preis 1995. The role of RET proto-oncogene mutation analysis in the diagnosis of multiple endocrine neoplasia type 2 (MEN 2) gene carriers and in the discrimination of sporadic and familial medullary thyroid carcinomas and pheochromocytomas.
    Komminoth P
    Verh Dtsch Ges Pathol; 1995; 79():L-LV. PubMed ID: 8600671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiple endocrine neoplasia type 2A with the identical somatic mutation in medullary thyroid carcinoma and pheochromocytoma without germline mutation at the corresponding site in the RET proto-oncogene.
    Akama H; Noshiro T; Kimura N; Shimizu K; Watanabe T; Shibukawa S; Nakai S; Miura W; Ito S; Miura Y
    Intern Med; 1999 Feb; 38(2):145-9. PubMed ID: 10225670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of minute medullary thyroid carcinoma in multiple endocrine neoplasia 2A families first diagnosed by DNA analysis of RET proto-oncogene mutations: a case report.
    Yamashita T; Lihara M; Okamoto J; Kanbe M; Ito Y; Kawakami M; Egawa S; Yamaguchi K; Obara T
    Jpn J Clin Oncol; 1997 Feb; 27(1):42-5. PubMed ID: 9070340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A rare missense variant in RET exon 8 in a Portuguese family with atypical multiple endocrine neoplasia type 2A.
    Martins AF; Martins JM; do Vale S; Dias T; Silveira C; da Silva IR; Carmo-Fonseca M
    Hormones (Athens); 2016 Jul; 15(3):435-440. PubMed ID: 27838608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Penetrance of inherited medullary thyroid carcinoma and genotype-phenotype correlation in a large multiple endocrine neoplasia type 2A family with C634Y RET mutation.
    González-Yebra B; Medrano ME; Mantilla A; Palma V; Colin C; Hernández DM; Tapia J; Dawson B; Salcedo M
    Endocr Pathol; 2003; 14(1):71-80. PubMed ID: 12746565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Detection of RET-proto-oncogene mutations in the diagnosis of Type 2 endocrine neoplasia (MEN 2)].
    Komminoth P; Muletta-Feurer S; Soltermann A; Gemsenjäger E; Bürgi H; Staub JJ; Schönle E; Fried M; Vetter W; Spinas GA; Heitz PU
    Schweiz Med Wochenschr; 1996 Aug; 126(31-32):1329-38. PubMed ID: 8765374
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of RET protooncogene point mutations distinguishes heritable from nonheritable medullary thyroid carcinomas.
    Komminoth P; Kunz EK; Matias-Guiu X; Hiort O; Christiansen G; Colomer A; Roth J; Heitz PU
    Cancer; 1995 Aug; 76(3):479-89. PubMed ID: 8625130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple endocrine neoplasia 2A due to a unique C609S RET mutation presents with pheochromocytoma and reduced penetrance of medullary thyroid carcinoma.
    Kinlaw WB; Scott SM; Maue RA; Memoli VA; Harris RD; Daniels GH; Porter DM; Belloni DR; Spooner ET; Ernesti MM; Noll WW
    Clin Endocrinol (Oxf); 2005 Dec; 63(6):676-82. PubMed ID: 16343103
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Presymptomatic DNA screening in families with multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma.
    Frilling A; Dralle H; Eng C; Raue F; Broelsch CE
    Surgery; 1995 Dec; 118(6):1099-103; discussion 1103-4. PubMed ID: 7491529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis of multiple endocrine neoplasia [MEN] 2A, 2B and familial medullary thyroid cancer [FMTC] by multiplex PCR and heteroduplex analyses of RET proto-oncogene mutations.
    Kambouris M; Jackson CE; Feldman GL
    Hum Mutat; 1996; 8(1):64-70. PubMed ID: 8807338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiple endocrine neoplasia type 2A. Study of a family.
    Correia MJ; Lopes LO; Bugalho MJ; Cristina L; Santos AI; Bordalo AD; Pinho B; da Silva HL; Gonçalves MD; Ribeiro C; Tuna JL
    Rev Port Cardiol; 2000 Jan; 19(1):11-31. PubMed ID: 10731788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.
    Egawa S; Futami H; Takasaki K; Iihara M; Okamoto T; Kanbe M; Ohi T; Saio Y; Miyauchi A; Takiyama Y; Koga M; Miyanaga K; Inoue K; Mitsuyama S; Nomura Y; Takei H; Mugiya S; Ishida O; Zeze F; Shakutsui S; Inoue H; Oya H; Yoshimura A; Ishizuka S; Yamaguchi K
    Jpn J Clin Oncol; 1998 Oct; 28(10):590-6. PubMed ID: 9839497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s.
    Zedenius J; Wallin G; Hamberger B; Nordenskjöld M; Weber G; Larsson C
    Hum Mol Genet; 1994 Aug; 3(8):1259-62. PubMed ID: 7987299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET oncogene mutations in medullary thyroid carcinoma in Mexican families.
    González B; Salcedo M; Medrano ME; Mantilla A; Quiñónez G; Benítez-Bribiesca L; Rodríguez-Cuevas S; Cabrera L; de León B; Altamirano N; Tapia J; Dawson B
    Arch Med Res; 2003; 34(1):41-9. PubMed ID: 12604374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low frequency of germline mutations in the RET proto-oncogene in patients with apparently sporadic medullary thyroid carcinoma.
    Eng C; Mulligan LM; Smith DP; Healey CS; Frilling A; Raue F; Neumann HP; Ponder MA; Ponder BA
    Clin Endocrinol (Oxf); 1995 Jul; 43(1):123-7. PubMed ID: 7641404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.